DOCSLIB.ORG

Poster Session Iiiwednesday, December 10, 2014

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Poster Session Iiiwednesday, December 10, 2014 Neuropsychopharmacology (2014) 39, S473–S647 & 2014 American College of Neuropsychopharmacology. All rights reserved 0893-133X/14 www.neuropsychopharmacology.org Wednesday, December 10, 2014 cated higher intake of this dose under low reinforcement schedules by CPP-B6 mice, and intake was predicted under both FR1 and F2 reinforcement schedules by CPP Score. W1. Validation of a Procedurally Simple Murine Model However, there were no group differences in elasticity. of Methamphetamine Addiction Vulnerability/ Immunoblotting revealed higher Homer2 expression, which Resiliency in Mice is consistent with prior results from MA-sensitized B6 mice and mice selectively bred for high MA intake and might Matan Cohen, Hanna Barrett, Nimrita Singh, underpin the addiction vulnerable phenotype of CPP-B6 Melissa Wroten, Gema Olivarria, Lana Bubalo, mice. Tod Kippin, Karen Szumlinski* Conclusions: Together, these results provide predictive and University of California at Santa Barbara, Santa Barbara, construct validity for our B6 place-conditioning model California as a high-throughput tool for studying the biobehavioral mechanisms of MA addiction vulnerability/resilience of to Background: Individual variation exists with respect to the our understanding of the etiology and treatment of MA development and severity of drug addiction and this addiction. individual variability reflects a combination of environ- Keywords: resiliency, addiction, vulnerability, homer. mental and genetic factors. However, the biochemical Disclosure: Nothing to Disclose. correlates of addiction vulnerability/resiliency are severely understudied, particularly to the highly addictive psycho- motor stimulant methamphetamine (MA). Even in pre- W2. Robust, Scalable, and Cost-effective High sumably genetically homogeneous populations of C57BL/6J Throughput Production of iPSC-derived Neural (B6) mice, marked variability exists with respect to the Stem Cells/Early Neural Progenitor Cells and Their capacity of repeated MA (4X2 mg/kg) to elicit place- Differentiation into Glutamatergic Neurons conditioning, an index of MA’s motivational/affective valence. While approximately 50% of B6 mice exhibit a Leonardo D’Aiuto, Yun Zhi, Dhanjit Das, Madeleine conditioned-preference (CPP) for a MA-paired environ- Wilcox, Jon Johnson, Lora McClain, Roberto Di Maio, ment, approximately 12% show conditioned aversion Mark Schurdak, Paolo Piazza, Luigi Viggiano, (CPA), and the remaining mice exhibit ambivalence or no Paul Kinchington, Ayantika Bhattacharjee, conditioned response (Neutral). Vishwajit Nimgaonkar* Methods: We tested the predictive validity of studying University of Pittsburgh School of Medicine, Pittsburgh, inbred B6 mice under simple place-conditioning procedures Pennsylvania as a high-throughput strategy for the study of MA addiction vulnerability/resiliency, by correlating phenotype with MA- Background: Induced pluripotent stem cell (iPSC)-based induced locomotor activity, by assaying CPP-, Neutral- and technologies have revolutionized research into human CPA-B6 mice in a place-conditioning version of the diseases by enabling the generation of specified cells in a extinction/reinstatement paradigm, as well as an oral MA renewable manner from individuals of interest. Human self-administration paradigm (10-40 mg/L). We also tested iPSC-based models also offer an unprecedented opportunity the construct validity of this model by examining for to perform high throughput screens of novel drugs for phenotypic differences in the expression of glutamate- neurological and neurodegenerative diseases. Such screens related proteins within the nucleus accumbens core. require a robust and scalable method to generate large Results: CPP Score was inversely correlated with acute MA- numbers of uniformly distributed, differentiated mature induced locomotor hyperactivity, but positively correlated neuronal cells. Currently, available methods based on with the extent to which mice developed locomotor differentiation of embryoid bodies (EBs) or directed sensitization during MA-conditioning. The MA-conditioned differentiation of adherent culture systems are either response was more resistant to extinction in CPP-B6 mice expensive or are not scalable. vs. CPA counterparts and a 2 mg/kg MA challenge injection Methods: We developed a protocol that enabled high reinstated the conditioned response following extinction throughput generation of neuronal stem cells (NSCs)/early only in CPP-B6 mice. CPP-B6 mice also exhibited greater neural progenitor cells (eNPCs) from iPSCs. These cells MA-directed responding during the first several days of were stored or transferred into 384 well plates and self-administration when 20 mg/L MA served as the differentiated into neurons. At least twenty-four 384-well reinforcer, but did not differ from Neutral or CPA mice plates at a density of 3.5 x103 NSCs/NPCs/well could be regarding MA intake of this dose at any time during study. generated from a confluent 6-well plate of iPSCs in 4 weeks When the dose-response function for MA intake was at a cost of $ 28/plate. examined, CPP-B6 mice consumed higher amounts of the Results: Following culture in neurobasal medium supple- 10 mg/L and 40 mg/L solutions, and their CPP Score mented with B27 and BDNF, NSCs/eNPCs principally predicted the intake of the 10 mg/L dose. A comparison of differentiated into glutamatergic neurons expressing mar- response elasticity in response to 10 mg/L MA under kers characteristic of forebrain layer 3 pyramidal cells. increasing schedules of reinforcement (FR1-FR40), indi- Whole-cell patch-clamp experiments indicated that most ACNP 53rd Annual Meeting Abstracts S474 iPSC-derived neurons express functional ligand-gated measured by the change in PANSS total score and CGI-S, channels. respectively. All doses of brexpiprazole were well tolerated. Conclusions: The procedure detailed here enables robust, Keywords: Schizophrenia, Phase III trial, Brexpiprazole, scalable, and cost-effective generation of neurons in Efficacy and safety. numbers required for high-throughput screening. Disclosure: I (Christoph Correll) have been a consultant Keywords: Induced pluripotent stem cells (iPSCs), Neuronal and/or advisor to or have received honoraria from: stem cells (NSCs), High throughput screening, In vitro Actelion, Alexza; American Academy of Child and Adoles- neuronal differentiation. cent Psychiatry, Bristol-Myers Squibb (BMS), Cephalon, Eli Disclosure: Nothing to Disclose. Lilly, Genentech, Gerson Lehrman Group, IntraCellular Therapies, Lundbeck, Medavante, Medscape, Merck, Jans- sen/J&J, Otsuka, Pfizer, ProPhase, Roche, Sunovion, Take- da, Teva and Vanda. Income sources and equity of $10,000/ W3. Brexpiprazole for the Treatment of Acute year or greater: BMS, Janssen/J&J, Lundbeck, Otsuka, Pfizer, Schizophrenia: A Randomized, Controlled Trial ProPhase. Financial involvement with a company constitut- ing45% of personal income: BMS, Lundbeck, Otsuka, Christoph Correll*, Aleksandar Skuban, James Youakim, Pfizer, ProPhase. Funding received from: BMS, Feinstein John Ouyang, Mary Hobart, Stephanie Pfister, Robert Institute for Medical Research, Janssen/J&J, National McQuade, Margaretta Nyilas, William Carson, Raymond Institute of Mental Health, National Alliance for Research Sanchez in Schizophrenia and Depression and Otsuka. Drs. Skuban, Hofstra North Shore-LIJ School of Medicine/Zucker Youakim, Ouyang, Hobart, Pfister, McQuade, Nyilas, Hillside Hospital, Glen Oaks, New York Carson and Sanchez are employees of Otsuka Pharmaceu- tical Commercialization and Development, Inc. Funding for Background: To evaluate the efficacy, and safety/tolerability this study was provided by Otsuka Pharmaceutical Com- of brexpiprazole in patients with acute schizophrenia. mercialization and Development, Inc. (Princeton, USA) and Methods: This was a phase III, multicenter, randomized, H. Lundbeck A/S (Valby, Denmark). double-blind, placebo-controlled trial (NCT01396421). Pa- tients with acute schizophrenia were randomized to fixed doses of brexpiprazole 4 mg, 2 mg, 0.25 mg, or placebo W4. A Pooled Analysis of 3 Randomized, Placebo- (2:2:1:2) for 6 weeks. The primary efficacy endpoint was Controlled, Phase 3 Studies Evaluating the Efficacy, change in Positive and Negative Syndrome Scale (PANSS) Safety, and Tolerability of Adjunctive Armodafinil in total score from baseline to week 6; key secondary endpoint Bipolar I Depression was the change in Clinical Global Impression-Severity Scale (CGI-S) score at week 6. Efficacy analyses were conducted Mark Frye*, Jess Amchin, Ronghua Yang, Terrence Ketter using mixed model repeated measures (MMRM), including Mayo Clinic, Rochester, Minnesota treatment, visit, site and treatment-by-visit interaction as fixed effects, and baseline score-by-visit as covariate. A gate Background: Depressive episodes associated with bipolar I keeping average effect method was applied to control for disorder may warrant adjunctive pharmacotherapy. Indeed, multiple comparisons (at an alpha level of 0.05) before lurasidone is FDA-approved as adjunct therapy with lithium proceeding with the comparisons for 2 mg and 4 mg or valproate for bipolar I depression. Armodafinil (R- brexpiprazole versus placebo. The 0.25 mg group was modafinil) is a wakefulness-promoting, low-affinity dopa- included to establish a non-effective or minimally effective mine transport inhibitor currently approved in the US for dose range of brexpiprazole. the treatment of excessive sleepiness associated with Results: The gate keeper test of
Load more

Recommended publications
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,381,189 B2 Green Et Al
    US009381189B2 (12) United States Patent (10) Patent No.: US 9,381,189 B2 Green et al. (45) Date of Patent: Jul. 5, 2016 (54) INGREDIENTS FOR INHALATION AND (56) References Cited METHODS FOR MAKING THE SAME U.S. PATENT DOCUMENTS (75) Inventors: Matthew Michael James Green, 4,582,265 A * 4/1986 Petronelli ....................... 241.95 Wiltshire (GB); Richard Michael Poole, 6,257,233 B1 7/2001 Burr et al. 2004/01 18007 A1* 6/2004 Chickering et al. ............ 34/360 Wiltshire (GB) 2006, O257491 A1* 11, 2006 Morton et al. ... 424/489 (73) Assignee: VECTURA LIMITED, Wiltshire (GB) 2008/0063719 A1 3/2008 Morton et al. ................ 424/489 (*) Notice: Subject to any disclaimer, the term of this FOREIGN PATENT DOCUMENTS patent is extended or adjusted under 35 EP O709086 A2 5, 1996 U.S.C. 154(b) by 641 days. EP 14981 16 A1 1, 2005 GB 2387781 A 10, 2003 JP 2005298.347 10/2005 (21) Appl. No.: 13/514,672 JP 200954.1393 11, 2009 JP 2012,542618 6, 2012 (22) PCT Fled: Dec. 8, 2010 WO 96.23485 A1 8, 1996 WO 9703649 A1 2, 1997 (86) PCT NO.: PCT/GB2O10/052053 WO O2OO197 A1 1, 2002 WO O243701 A2 6, 2002 S371 (c)(1), WO 2005105043 A2 11/2005 Aug. 20, 2012 WO 2007053904 A1 5/2007 (2), (4) Date: WO 2008.000482 1, 2008 (87) PCT Pub. No.: WO2O11AO70361 WO 2009095684 A1 8, 2009 OTHER PUBLICATIONS PCT Pub. Date: Jun. 16, 2011 Brunauer et al. "Adsorption of Gases in Multimolecular Layers'. J. (65) Prior Publication Data Am.
    [Show full text]
  • View a Copy of This Licence, Visit
    LaPelusa et al. Microbiome (2021) 9:2 https://doi.org/10.1186/s40168-020-00951-5 MEETING REPORT Open Access Microbiome for Mars: surveying microbiome connections to healthcare with implications for long-duration human spaceflight, virtual workshop, July 13, 2020 Michael LaPelusa1*†, Dorit Donoviel2, Sergio E. Branzini3, Paul E. Carlson Jr4, Stephanie Culler5, Amrita K. Cheema6, Rima Kaddurah-Daouk7, Denise Kelly8, Isabelle de Cremoux8, Rob Knight9, Rosa Krajmalnik-Brown10,11, Stephen L. Mayo12, Sarkis K. Mazmanian12, Emeran A. Mayer13,14,15, Joseph F. Petrosino16 and Keith Garrison17*† Abstract The inaugural “Microbiome for Mars” virtual workshop took place on July 13, 2020. This event assembled leaders in microbiome research and development to discuss their work and how it may relate to long-duration human space travel. The conference focused on surveying current microbiome research, future endeavors, and how this growing field could broadly impact human health and space exploration. This report summarizes each speaker’s presentation in the order presented at the workshop. Keywords: Microbiome, Spaceflight, Radiation, Multiple sclerosis, Behavior, Gut-brain axis, Metabolome, Sequencing, Autism spectrum disorder, Fecal microbiota transplants, Live biotherapeutic products Introduction disruptive scientific discoveries and technological ad- An unusual intersection of disciplines took place on July vances that promise to reduce human health risks and 13, 2020. Microbiome researchers applied their under- performance in long-duration space missions. It does this standing of the human microbiome to challenges facing in part by generating scientific content and opportunities future long-duration human space flight. The conference for communities outside of NASA to learn about human was attended virtually by over 500 unique participants deep-space exploration challenges.
    [Show full text]
  • (Esi Scheme) Laxminagar, Ajmer Road, Jaipur-302006
    DIRECTORATE, MEDICAL & HEALTH SERVICES, (E.S.I. SCHEME) LAXMINAGAR, AJMER ROAD, JAIPUR-302006 Tel/Fax 0141-2223572,www.health.rajasthan.gov.in/esi E-Mail [email protected],[email protected] Ref. No. F434/ESI/Store/LabEmp/2017/5540 Dated:01/11/2017 E- Tender Document For “E- Tender forAnalysis of Drugs, Cotton, Gauzes, Bandage & Other items” For The Office of the Director cum Ex-officio Dy. Secretary, Medical & Health Services ESI Scheme Rajasthan, Laxmi Nagar, Ajmer Road, Jaipur & attached ESIS Institutions in Rajasthan ( for the period of two years from the date of award. ) ( Non-transferable ) Price of Tender Document Rs. 2000/- Last date & time of submission of Technical & Financial Bids is 11.12.17 at 1:30 pm Date & time of online opening of Technical Bid is 11.12.17 at 3:00 pm Visit Us At http://sppp.raj.nic.in, www.dipronline.org, http://eproc.rajasthan.gov.in, www.health.rajasthan.gov.in/esi Our Address: DIRECTORATE, MEDICAL & HEALTH SERVICES, (E.S.I. SCHEME) LAXMINAGAR, AJMER ROAD, JAIPUR-302006 1/71 DIRECTORATE, MEDICAL & HEALTH SERVICES, (E.S.I. SCHEME) LAXMINAGAR, AJMER ROAD, JAIPUR-302006 Tel/Fax 0141-2223572,www.health.rajasthan.gov.in/esi E-Mail [email protected],[email protected] Ref.No.F434/ESI/Store/LabEmp/2017/ 5540 Dated:01/11/2017 E-bids in two separate bids (Technical & Financial) for the Empanelment of Analytic Testing Laboratories For The Test and Analysis of drugs, cotton, bandage, gauze & other items. Brief Details of E-Tender Estimated Cost : Rs 50 lacs EMD (Bid Security)Rs 100000/- RISL processing fees Rs 1000/- Cost of the Tender Document Rs 2000/- Performance Security 5% of contract value Services Required:- The service of analysis of drugs, cotton, gauze, bandages & other items are required in the office of the Director cum Ex- officio Dy.
    [Show full text]
  • Nomination Background: Ketamine Hydrochloride (CASRN: 1867-66-9)
    KETAMINE Nomination TABLE OF CONTENTS Page 1.0 BASIS OF NOMINATION 1 2.0 BACKGROUND INFORMATION 1 3.0 CHEMICAL PROPERTIES 2 3.1 Chemical Identification 2 3.2 Physico-Chemical Properties 3 3.3 Purity and Commercial Availability 4 4.0 PRODUCTION PROCESSES AND ANALYSIS 6 5.0 PRODUCTION AND IMPORT VOLUMES 7 6.0 USES 7 7.0 ENVIRONMENTAL OCCURRENCE 7 8.0 HUMAN EXPOSURE 7 9.0 REGULATORY STATUS 7 10.0 CLINICAL PHARMACOLOGY 7 11.0 TOXICOLOGICAL DATA 13 11.1 General Toxicology 13 11.2 Neurotoxicology 14 12.0 CONCLUSIONS 15 APPENDIX A 17 APPENDIX B 23 APPENDIX C 27 1 KETAMINE 1.0 BASIS OF NOMINATION Ketamine, a noncompetitive NMDA receptor blocker, has been used extensively off - label as a pediatric anesthetic for surgical procedures in infants and toddlers. Recently, Olney and coworkers have demonstrated severe widespread apoptotic degeneration throughout the rapidly developing brain of the 7-day-old rat after ketamine administration. Recent research at FDA has confirmed and extended Olney’s observations. These findings are cause for concern with respect to ketamine use in children. The issue of whether the neurotoxicity found in this animal model (rat) has scientific and regulatory relevance for the pediatric use of ketamine relies heavily upon confirmation of these findings that may be obtained from the conduct of an appropriate study in non-human primates. 2.0 BACKGROUND INFORMATION The issue of potential ketamine neurotoxicity in children surfaced as a result of FDA’s reluctance to approve an NIH pediatric clinical trial using this compound because of its documented neurotoxic effects in young rats (published in several papers over the last ten years by Olney and co-workers).
    [Show full text]
  • The Effects of Ketamine on Dopaminergic Function
    THE EFFECTS OF KETAMINE ON DOPAMINERGIC FUNCTION Michelle Kokkinou Psychiatric Imaging Group London Institute of Medical Sciences (LMS), Medical Research Council (MRC) Faculty of Medicine, Imperial College London Thesis submitted for the degree of Doctor of Philosophy 1 Declaration of originality The experiments described and data analysis were part of my own work, unless otherwise stated. The work was conducted at the London Institute of Medical Sciences (LMS) in collaboration with Imanova Ltd. Specialist pre-clinical imaging analysis was conducted in collaboration with Mattia Veronese (King’s College London). Specialist meta-analysis was conducted in collaboration with Abhishekh Ashok. Peer-reviewed accepted paper Michelle Kokkinou, Abhishekh H Ashok, Oliver D Howes. The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders. Molecular Psychiatry. Oct 3. doi: 10.1038/mp.2017.190. Published conference abstracts arising from this thesis Chapters 3&4: Howes OD., Kokkinou M. The Effects of Repeated NMDA Blockade with Ketamine on Dopamine and Glutamate Function. Biological Psychiatry. 72nd Annual Scientific Convention and Meeting. https://doi.org/10.1016/j.biopsych.2017.02.091 Chapters 4&5: Kokkinou M, Irvine EE, Bonsall DR Ungless MA, Withers DJ, Howes OD. Modulation of sub-chronic ketamine-induced locomotor sensitisation by midbrain dopamine neuron firing. European Neuropsychopharmacology (ENP) Chapters 3 & 4 are in preparation for publication. Presentation regarding the experiments in this thesis British Association for Psychopharmacology Meeting July 2017. Midbrain dopamine neuron firing mediates the effects of ketamine treatment on locomotor activity: A DREADD experiment 2 Copyright Declaration The copyright of this thesis rests with the author and is made available under a Creative Commons Attribution Non-Commercial No Derivatives Licence.
    [Show full text]
  • Pharmacological Treatment Options for Alcohol Use Disorder*
    Dusunen Adam The Journal of Psychiatry and Neurological Sciences 2015;28:283-300 Editorial / Editoryal DOI: 10.5350/DAJPN20152804001 Pharmacological Treatment Cuneyt Evren1, Muge Bozkurt2 1Assoc. Prof. Dr., 2Psychiatrist, Bakirkoy Training and Options for Alcohol Use Research Hospital for Psychiatry, Neurology and Neurosurgery, Alcohol and Drug Research, Treatment and Training Center (AMATEM), Disorder* Istanbul - Turkey Address reprint requests to / Yazışma adresi: Assoc. Prof. Dr. Cuneyt Evren, Bakirkoy Training and Research Hospital for Psychiatry, Neurology and Neurosurgery, Alcohol and Drug Research, Treatment and Training Center (AMATEM), Istanbul, Turkey Phone / Telefon: +90-212-409-1515/2111, Fax / Faks: +90-212-409-1590, E-mail address / Elektronik posta adresi: [email protected] *Abridged version of the “Therapeutic Guideline for Alcohol Use Disorder” prepared by the Working Group Therapeutic Guideline for Alcohol Use Disorder. PHARMACOLOGICAL TREATMENT assess information obtained from studies regarding OPTIONS FOR ALCOHOL USE DISORDER drug treatments used in clinical practice today, which are summarized in Table 1. However, when examining Alcohol Use Disorder (AUD) and other alcohol- study results for pharmacological treatments, we related health problems are a significant public health immediately have to remember that all of those issue all over the world. The World Health Organization (WHO) reports that each year 3.3 million people lose Table 1: Drugs used for the therapy of alcohol use their lives due to harmful alcohol use, with 5.9% of all disorder (AUD) deaths being related to alcohol consumption (1). It has Drugs for AUD approved in Turkey been estimated that in 2010, the economic burden of Disulfiram Naltrexone alcohol-related costs was 155.8 billion Euro, of which Acamprosate 60% were connected to alcohol addiction (2).
    [Show full text]
  • Reproducibility of Behavioral Phenotypes in Mouse Models - a Short History with Critical and Practical Notes
    Reproducibility of behavioral phenotypes in mouse models - a short history with critical and practical notes Vootele Voikar Neuroscience Center and Laboratory Animal Center, Helsinki Institute of Life Science Correspondence: Mustialankatu 1 G Helsinki, Finland [email protected] Progress in pre-clinical research is built on endorsed by more than 1000 journals so far, reproducible findings, yet reproducibility has awareness of researchers and the quality of different dimensions and even meanings. Indeed, publications have not been sufficiently improved the terms reproducibility, repeatability, and (13-15). In order to facilitate and enhance replicability are often used interchangeably, implementation of the ARRIVE guidelines, a although each has a distinct definition. Moreover, revised version with exhaustive explanation and reproducibility can be discussed at the level of elaborative documentation was recently published methods, analysis, results, or conclusions (1, 2). (16, 17). Despite these differences in definitions and Paradigm shift. Mice and rats are the most dimensions, the main aim for an individual widely used model animals in basic biomedicine. research group is the ability to develop new However, there has been a drastic change in the studies and hypotheses based on firm and reliable relative use of these two rodent species over time findings from previous experiments. In practice (Figure 1). Historically, the rat was the model of this wish is often difficult to accomplish. In this choice for behavioral studies but from the review, issues affecting reproducibility in the field beginning of 1990s a sharp shift from rats to mice of mouse behavioral phenotyping are discussed. took place. Obviously, this was due to rapid Crisis in reproducibility.
    [Show full text]
  • Symposium Program September 22-23, 2014 | Joseph B
    Symposium Program September 22-23, 2014 | Joseph B. Martin Conference Center Harvard Medical School | Boston, Massachusetts, USA Unrestricted Educational Grants provided by: Monday, September 22, 2014 7:00 a.m. Registration & Breakfast 8:00 a.m. Welcome and Program Overview – W. Allan Walker, MD, Director, Division of Nutrition, Harvard Medical School 8:10 a.m. Opening Keynote - “Manipulating the Microbiota: Beyond Traditional Probiotics and Fecal Transplant” R. Balfour Sartor, MD Distinguished Professor of Medicine, Microbiology and Immunology, Director, UNC Multidisciplinary Center for IBD Research and Treatment, University of North Carolina SESSION IA: Pregnancy Moderator: Mary Ellen Sanders, PhD, Dairy & Food Culture Technologies 8:25 a.m. Keynote: “The Microbiota During Pregnancy” Omry Koren, PhD Assistant Professor, Faculty of Medicine, Bar Ilan University, Israel 8:55 a.m. Probiotic Use During Pregnancy for Protection Against Childhood Diseases Erika Isolauri, MD, D. Med. Sc Professor of Pediatrics, University of Turku, Finland Chief Physician, Department of Paediatrics, Turku University Hospital, Finland 9:25 a.m. Diet and Microbiotic Exposure During Pregnancy and Immune Protection Against Allergic Manifestations Erika von Mutius, MD, MSc Professor of Pediatrics, Head of Asthmas and Allergy Department, Dr. von Hauner Children’s Hospital, Germany 9:55 a.m. Discussion 10:20 a.m. Break SESSION IB: Neonatal Period Moderator: W. Allan Walker, MD, Harvard Medical School 10:45 a.m. Keynote: “Development of Human Infant Intestinal Microbiota” David A. Relman, MD Thomas C. and Joan M. Merigan Professor, Departments of Medicine and of Microbiology and Immunology, Stanford University 11:15 a.m. Antibiotics and Neonatal Colonization Martin J. Blaser, MD Muriel and George Singer Professor of Medicine, Professor of Microbiology, Director, Human Microbiome Program, New York University Langone Medical Center 11:45 a.m.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • The Era of Mental Health: a New Health Paradigm in Europe
    IBREA REPORT The Era of Mental Health: A New Health Paradigm in Europe Volume 10 | May 2018 IBREA, International Brain Education Association IBREA understands that the science and technology of today came from the human brain and believes that the key to solving the crisis we face today also lies in the human brain. Based on this understanding, IBREA was established with the purpose of creating a better future for the humankind by sharing the philosophy, principles of Brain Education. IBREA is a Non-governmental Organization associated with the United Nations Department of Public Information, and has participated to the UN Global Compact since 2009. Contents The Era of Mental Health: A New Health Paradigm in Europe 01 The International Brain Education Conference was held in London, attended by over 300 people from 12 countries in Europe. 04 [Interview] Jung Hee Jun, the Director of the Integrated Headquarters of the Body & Brain, Europe 06 [Interview with a participating country I] Katrien Boucique in Belgium A side-effect of universal medical care is the excessive dependence on the medical system 08 [Interview with a participating country II] Aleksandra and Peter Mason in Poland Belly Button Healing, a brain health method addressing intestinal health, receives positive reviews on a TV show in Poland 11 [Interview with a participating country III] Sang-woo Park in Russia Brain Education is an educational system designed to develop the potential of the brain. 13 [Interview with a participating country IV] Jan Sladek in Slovakia Discovering my own value is the most important life skill to create a happy and fulling life.
    [Show full text]
  • 56Th Annual Teratology Society Meeting
    54th Annual Meeting Birth Defects Research (Part A) 106:309–347 (2016) This event has been accredited by the McGill Center for Continuing Health Professional Education. 29th Annual Meeting for Organization of the Teratology Information Specialists (OTIS) June 25–28, 2016 40th Annual Meeting of the Developmental Neurotoxicology Society (DNTS) June 26–29, 2016 All text and graphics are © 2016 by the Teratology Society unless noted. River Walk photo courtesy of Staurt Dee/SACVB. Birth Defects Research (Part A) Clinical and Molecular Teratology 106:309–347 (2016) 310 TERATOLOGY SOCIETY PROGRAM Birth Defects Research (Part A) 106:309–347 (2016) TERATOLOGY SOCIETY PROGRAM 311 Program & Abstracts New Horizons in Birth Defects Research All text and graphics are © 2016 by the Teratology Society unless noted. River Walk photo courtesy of Staurt Dee/SACVB. Birth Defects Research (Part A) 106:309–347 (2016) 312 TERATOLOGY SOCIETY PROGRAM Program Overview FRIDAY, JUNE 24, 2016 12:00 Noon–1:30 PM 12:00 Noon–1:30 PM WEDNESDAY, JUNE 29, 2016 3:00 PM–6:00 PM Student and Postdoctoral Fellow Past Presidents’ and Honorees’ 6:30 AM–7:30 AM Council 1A Meeting Lunch Workshop Luncheon (By Invitation Only) Teratology Society 35th Annual Advancing Your Career in Birth Defects 3:00 PM–6:00 PM 1:30 PM–5:30 PM Volleyball Game Research and Prevention March of Dimes Symposium Registration Open (Advance Registration Required) 7:00 AM–2:30 PM New Approaches to the Treatment of Registration Open 3:00 PM–6:00 PM 1:30 PM–2:00 PM Birth Defects Speaker Ready Room Open 7:00 AM–2:30 PM F.
    [Show full text]